Hereditary breast and ovarian cancer: New genes, new treatments, new concepts;Familiäres mamma- und ovarialkarzinom: Neue gene, neue therapien, neue konzepte

Deutsches Arzteblatt

Volumn 108, Issue 19, 2011, Pages 323-330

  Meindl, Alfons ^a   Ditsch, Nina ^b   Kast, Karin ^c   Rhiem, Kerstin ^d   Schmutzler, Rita K ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; DOCETAXEL; OLAPARIB; PROTEIN; RAD51C PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; COLON CANCER; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA REPAIR; DRUG SENSITIVITY; FAMILIAL CANCER; GENDER; GENE MUTATION; GENETIC ANALYSIS; GERMANY; HIGH RISK PATIENT; HUMAN; INFORMATION PROCESSING; MASTECTOMY; MEDLINE; METASTASIS; MODULATION; MONOTHERAPY; MORPHOLOGICAL TRAIT; OVARY CANCER; PANCREAS CANCER; PROPHYLAXIS; REVIEW; SALPINGOOOPHORECTOMY; TUMOR GENE;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HETEROZYGOTE; HUMANS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960330300     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2011.0323     Document Type: Review

References (25)

1. Walsh T, Lee MK, Casadei S, et al.: Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010; 107: 12629-33.
2. Farmer H, McCabe N, Lord CJ, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21. (Pubitemid 40559006)
3. Fong PC, Boss DS, Yap TA, et al.: Inhibition of poly(ADP-ribose) polyme-rase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
4. Byrski T, Gronwald J, Huzarski T, et al.: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-9.
5. Audeh MW, Carmichael J, Penson RT, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 24; 376: 245-51.
6. Tutt A, Robson M, Garber JE, Domchek SM, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 24; 376: 235-44.
7. Warner E, et al.: A prospective study of breast cancer incidence and stage distribution in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; in press.
8. Domchek SM, Friebel TM, Singer CF, et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-75.
9. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-6. (Pubitemid 37310920)
10. Meindl A, Hellebrand H, Wiek C, et al.: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-4.
11. Turnbull C, Rahman N: Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 2008; 9: 321-45.
12. Weischer M, Bojesen SE, Ellervik C, Tyboerg-Hansen A, Nordestgaard BG: CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta- analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008; 26: 542-8. (Pubitemid 351264346)
13. Easton DF, Pooley KA, Dunning AM, et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93. (Pubitemid 47014426)
14. Antoniou AC, Spurdle AB, Sinilnikova OM, et al.: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008; 82: 937-48.
15. Foulkes WD, Stefansson IM, Chappuis PO, et al.: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-5. (Pubitemid 37279334)
16. Graeser MK, Engel Ch, Rhiem K, et al.: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 1-6.
17. Meijers-Heijboer H, van Geel B, van Putten WL, et al.: Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 and BRCA2 mutation. N Engl J Med 2001; 345: 159-64. (Pubitemid 32662123)
18. Kauff ND, Domchek SM, Friebel TM, et al.: Risk reducing Salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated Breast and Gynecologic Cancer: A multicenter, prospective Study. J Clin Oncol 2008; 26: 1331-7.
19. Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2. J Clin Oncol 2004; 22: 735-42. (Pubitemid 41095079)
20. Mitra AV, Bancroft EK, Barbachano Y, et al.: Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects agressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 2011; 107: 28-39.
21. Jacob DA, Bahra M, Langrehr JM, et al.: Combination therapy of poly-(ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J of Gastro-enterol and Hepatol 2007; 22: 738-48. (Pubitemid 46608375)
22. Kriege M, Brekelmans CT, Boetes C, et al.: Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-37.
23. Leach MO, Boggis CR, Dixon AK, et al.: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78. (Pubitemid 40744657)
24. Quinn JE, Kennedy RD, Mullan PB, et al.: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-8. (Pubitemid 37255167)
25. De Bono JS, Ashworth A: Translating cancer into targeted therapies. Nature 2010; 467: 543-9.